nyuuzyou/wikis huggingface dataset:
Bicalutamide (Casodex)

==General information==
Class/mechanism: Antiandrogen; non-steroidal androgen receptor inhibitor that competitively inhibits androgens by binding to cytosol androgen receptors.Bicalutamide (Casodex) package insert Bicalutamide (Casodex) package insert (locally hosted backup)
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, UpToDate Lexidrug, Medscape or the prescribing information.
==Diseases for which it is used==
*Prostate cancer
==Patient drug information==
*Bicalutamide (Casodex) package insert
*Bicalutamide (Casodex) patient drug information (Chemocare)Bicalutamide (Casodex) patient drug information (Chemocare)
*Bicalutamide (Casodex) patient drug information (UpToDate)Bicalutamide (Casodex) patient drug information (UpToDate)
==History of changes in FDA indication==
*1995-10-04: Initial accelerated approval for use in combination therapy with a luteinizing-hormone releasing hormone (LHRH) analogue for the treatment of advanced prostate cancer. (Based on Schellhammer et al. 1995)
**1997-12-12: Converted to regular approval for use in combination therapy with a luteinizing-hormone releasing hormone (LHRH) analogue for the treatment of advanced prostate cancer. (Based on Schellhammer et al. 1995)
==History of changes in EMA indication==
*1995-02-28: EURD
==History of changes in Health Canada indication==
*1995-11-02: Initial notice of compliance for use in combination therapy with either a luteinizing hormone releasing hormone (LHRH) analogue or surgical castration in the treatment of metastatic (Stage D2) prostate cancer. 
==Also known as==
*Brand names: Bical, Bicalmid, Bicalon, Bicatero, Binarex, Casodex, Cassotide, Cosudex, Calutide, Kalumid, Procalut, Prosmide, Utamide
==References==
Category:Drugs
Category:Oral medications
Category:First-generation nonsteroidal antiandrogens
Category:Prostate cancer medications
Category:FDA approved in 1995
Category:EMA approved in 1995
Category:Health Canada approved in 1995
Category:WHO Essential Cancer Medicine
Binimetinib (Mektovi)

==Mechanism of action==
From the NCI Drug Dictionary: An orally available inhibitor of mitogen-activated protein kinase kinase 1 and 2 (MEK1/2) with potential antineoplastic activity. Binimetinib, noncompetitive with ATP, binds to and inhibits the activity of MEK1/2.
==Diseases for which it is established==
*BRAF-mutant colorectal cancer
*BRAF-mutant melanoma
*BRAF-mutant NSCLC
*NRAS-mutant melanoma
==History of changes in FDA indication==
*2018-06-27: Initial FDA approval in combination with Encorafenib (Braftovi) for patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test. (Based on COLUMBUS)
*2023-10-11: Approved with Encorafenib (Braftovi) for adult patients with metastatic non-small cell lung cancer (NSCLC) with a BRAF V600E mutation, as detected by an FDA-approved test. (Based on PHAROS)
==History of changes in EMA indication==
*2018-09-20: Initial authorization as Mektovi. Binimetinib in combination with encorafenib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation. (Based on COLUMBUS and LOGIC-2)
*2020-04-30: Extension of indication to include encorafenib in combination with cetuximab, for the treatment of adult patients with metastatic colorectal cancer (CRC) with a BRAF V600E mutation, who have received prior systemic therapy.
==History of changes in Health Canada indication==
*2021-03-02: Initial notice of compliance in combination with encorafenib for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600 mutation, as detected by a validated test.
==History of changes in PMDA indication==
*2019-01-08: New approval for the treatment of unresectable melanoma with BRAF gene mutation.
*2020-11-27: New indication and a new dosage for the treatment of unresectable, advanced or recurrent BRAF mutation-positive colorectal cancer that has progressed after cancer chemotherapy.
==Also known as==
*Code names: ARRY-162, ARRY-438162, MEK-162
*Brand names: Mektovi
Category:Drugs
Category:Oral medications
Category:Mutation-specific medications
Category:MAP2K1 inhibitors
Category:MAP2K2 inhibitors
Category:Colorectal cancer medications
Category:Melanoma medications
Category:Non-small cell lung cancer medications
Category:EMA approved in 2018
Category:FDA approved in 2018
Category:Health Canada approved in 2021
Category:PMDA approved in 2019
Birtamimab (NEOD-001)

==Mechanism of action==
From the NCI Drug Dictionary: A monoclonal antibody against amyloid with potential use in the treatment of amyloid light chain (AL) and AA amyloidosis. Upon intravenous administration, anti-amyloid monoclonal antibody NEOD001 specifically binds to amyloid fibrils. This prevents the formation of amyloid deposits in certain organs and facilitates their clearance. It also reduces the level of amyloid deposits in organs and prevents organ dysfunction.
==Preliminary data==
Note: This is not meant to be an exhaustive list of preliminary results. References included in this section include non-randomized studies published in high-profile journals (e.g., NEJM) and experimental arms of phase 3 RCTs. Inclusion here is not an indication of impending regulatory approval, although many of these drugs do end up receiving approval by a regulatory authority.
===Light-chain (AL) amyloidosis===
# NEOD001-001: Gertz MA, Landau H, Comenzo RL, Seldin D, Weiss B, Zonder J, Merlini G, Schönland S, Walling J, Kinney GG, Koller M, Schenk DB, Guthrie SD, Liedtke M. First-in-Human Phase I/II Study of NEOD001 in Patients With Light Chain Amyloidosis and Persistent Organ Dysfunction. J Clin Oncol. 2016 Apr 1;34(10):1097-103. link to original article link to PMC article EuroPMC NCT01707264
==Also known as==
*Code name: NEOD-001
Category:Drugs
Category:Intravenous medications
Category:Anti-amyloid antibodies
Category:Light-chain (AL) amyloidosis medications (investigational)
Category:Halted drugs
Bivalirudin (Angiomax)

==General information==
Class/mechanism: Direct thrombin inhibitor, binds reversibly to free and clot-associated thrombin at its catalytic site and anion-binding exosite and inhibits its effects of catalyzing the formation of fibrin from fibrinogen, platelet aggregation, activation of protein C, and activation of coagulation factors V, VIII, and XIII.Bivalirudin (Angiomax) package insert Bivalirudin (Angiomax) package insert (locally hosted backup)Angiomax manufacturer's website
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, UpToDate Lexidrug, Medscape,or the prescribing information.
==Patient drug information==
*Brief patient counseling information can be found in the Bivalirudin (Angiomax) package insert
*Bivalirudin (Angiomax) patient drug information (UpToDate)Bivalirudin (Angiomax) patient drug information (UpToDate)
==Also known as==
*Brand names: Angiomax, Angiox
==References==
Category:Drugs
Category:Intravenous medications
Category:Anticoagulants
Category:Direct thrombin inhibitors
Category:Venous thromboembolism medications
Category:FDA approved in 2000
Bladder cancer - historical

Back to Top
The purpose of this page is to provide references to regimens that are obsolete, outdated, or of historical interest only. Is there a regimen missing from this list? See the main bladder cancer page for current regimens.
Last updated on 2024-07-23:2 regimens on this page
2 variants on this page
 
=Nonmuscle invasive bladder cancer=
==Intravesicular Doxorubicin monotherapy==
===Regimen===
Study 	Dates of enrollment	Evidence 	Comparator 	Comparative Efficacy
Martínez-Piñeiro et al. 1990	1980-1988 	Phase 3 (C)	1. BCG 	Shorter RFS
Martínez-Piñeiro et al. 1990	1980-1988 	Phase 3 (C)	2. Thiotepa	Not reported
Lamm et al. 1991 (SWOG 8216)	1983-1985 	Phase 3 (C)	BCG 	Seems to have shorter DFS
====Chemotherapy====
*Doxorubicin (Adriamycin) 50 mg intravesicularly once on day 1
7-day cycle for 4 cycles, then 1-month cycle for 11 cycles (approximately 1 year)
===References===
#Martínez-Piñeiro JA, Jiménez León J, Martínez-Piñeiro L Jr, Fiter L, Mosteiro JA, Navarro J, García Matres MJ, Cárcamo P. Bacillus Calmette-Guérin versus doxorubicin versus thiotepa: a randomized prospective study in 202 patients with superficial bladder cancer. J Urol. 1990 Mar;143(3):502-6. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC
#SWOG 8216: Lamm DL, Blumenstein BA, Crawford ED, Montie JE, Scardino P, Grossman HB, Stanisic TH, Smith JA Jr, Sullivan J, Sarosdy MF, Crissman JD, Coltman CA. A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guérin for transitional-cell carcinoma of the bladder. N Engl J Med. 1991 Oct 24;325(17):1205-9. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC
==Intravesicular Thiotepa monotherapy==
===Regimen===
Study 	Dates of enrollment	Evidence 	Comparator 	Comparative Efficacy
Martínez-Piñeiro et al. 1990	1980-1988 	Phase 3 (C)	1. BCG 	Shorter RFS
Martínez-Piñeiro et al. 1990	1980-1988 	Phase 3 (C)	2. Doxorubicin	Not reported
====Chemotherapy====
*Thiotepa (Thioplex) 50 mg intravesicularly once on day 1
===References===
#Martínez-Piñeiro JA, Jiménez León J, Martínez-Piñeiro L Jr, Fiter L, Mosteiro JA, Navarro J, García Matres MJ, Cárcamo P. Bacillus Calmette-Guérin versus doxorubicin versus thiotepa: a randomized prospective study in 202 patients with superficial bladder cancer. J Urol. 1990 Mar;143(3):502-6. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC
7-day cycle for 4 cycles, then 1-month cycle for 11 cycles (approximately 1 year)
Category:Bladder cancer regimens
Category:Historical regimens
Category:Disease-specific pages
Category:Urothelial carcinomas
Blastic plasmacytoid dendritic cell neoplasm

Back to Top
Last updated on 2024-07-23:1 regimens on this page
1 variants on this page
=Guidelines=
==NCCN==
*NCCN does not currently have guidelines at this granular level; please see NCCN Guidelines - Acute Myeloid Leukemia.
*2023: Pollyea et al. Acute Myeloid Leukemia, Version 3.2023, NCCN Clinical Practice Guidelines in Oncology EuroPMC
=All lines of therapy=
==Tagraxofusp monotherapy==
===Regimen===
Study 	Dates of enrollment 	Evidence
Frankel et al. 2014 (STU 012013-061) 	2013 to not reported	Phase 1/2, fewer than 20 pts
Pemmaraju et al. 2019 (STML-401-0114)	2014-2017 	Phase 1/2 (RT)
====Targeted therapy====
*Tagraxofusp (Elzonris) 12 mcg/kg IV over 15 minutes once per day on days 1 to 5
21-day cycles
===References===
# STU 012013-061: Frankel AE, Woo JH, Ahn C, Pemmaraju N, Medeiros BC, Carraway HE, Frankfurt O, Forman SJ, Yang XA, Konopleva M, Garnache-Ottou F, Angelot-Delettre F, Brooks C, Szarek M, Rowinsky E. Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients. Blood. 2014 Jul 17;124(3):385-92. Epub 2014 May 23. link to original article link to PMC article EuroPMC NCT00397579
# STML-401-0114: Pemmaraju N, Lane AA, Sweet KL, Stein AS, Vasu S, Blum W, Rizzieri DA, Wang ES, Duvic M, Sloan JM, Spence S, Shemesh S, Brooks CL, Balser J, Bergstein I, Lancet JE, Kantarjian HM, Konopleva M. Tagraxofusp in blastic plasmacytoid dendritic-cell neoplasm. N Engl J Med. 2019 Apr 25;380(17):1628-1637. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC NCT02113982
##Update: Pemmaraju N, Sweet KL, Stein AS, Wang ES, Rizzieri DA, Vasu S, Rosenblat TL, Brooks CL, Habboubi N, Mughal TI, Kantarjian H, Konopleva M, Lane AA. Long-Term Benefits of Tagraxofusp for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm. J Clin Oncol. 2022 Sep 10;40(26):3032-3036. Epub 2022 Jul 12. link to original article link to PMC article EuroPMC
Category:Blastic plasmacytoid dendritic cell neoplasm regimens
Category:Disease-specific pages
Category:Myeloid neoplasms
Bleeding disorders and risk

Incomplete information; this section will be expanded, clarified, and with references added in the future.
==Initial evaluation==
*Bleeding history (acquired or inherited disorder?)
**Spontaneous or provoked by surgery, tooth extraction, etc.
**Tolerance of prior surgery
**Menses
**Mucocutaneous bleeding, petechiae, oozing at line sites
**Bruising, hemarthrosis
**Family history--known hemophilia A, hemophilia B, von Willebrand disease (VWD), platelet function disorder
**Need for transfusion or product
*History of trauma, surgery
*PT/INR
*PTT
*Platelet count
*+/- fibrinogen (DIC), D-dimer, fibrin/fibrinogen degradation products (FDP)
*Kidney disease (uremia)
*Medications: anticoagulants, antiplatelet medications such as aspirin and Clopidogrel (Plavix), NSAIDS, antidepressants which cause decrease in platelet function
*Vitamin C (scurvy). No fruits or vegetables in diet?
==Bleeding Score==
This is a quantitative assessment of bleeding risk based on history, and can predict the likelihood of VWD Type I.
*ASH Pocket Guides App contains several calculators including the bleeding score calculator
# Tosetto A, Rodeghiero F, Castaman G, Goodeve A, Federici AB, Batlle J, Meyer D, Fressinaud E, Mazurier C, Goudemand J, Eikenboom J, Schneppenheim R, Budde U, Ingerslev J, Vorlova Z, Habart D, Holmberg L, Lethagen S, Pasi J, Hill F, Peake I. A quantitative analysis of bleeding symptoms in type 1 von Willebrand disease: results from a multicenter European study (MCMDM-1 VWD). J Thromb Haemost. 2006 Apr;4(4):766-73. link to original article EuroPMC
==Abnormal PT/INR or PTT==
*1:1 mixing study (50/50 mixing study, circulating anticoagulant)
*Liver disease
*Elevated PT only
**Vitamin K deficiency
***Warfarin
***Dietary habits
***Antibiotic use
***Malnutrition
***Increased gut motility
**Deficiency or inhibitor of factor VII 
**Lupus anticoagulant (rarely)
*Elevated PTT only
**Heparin
**Deficiencies of factor VIII, factor IX, factor XI, factor XII, or inhibitors.
**Not associated with increased bleeding risk: Prekallikrein deficiency, high molecular weight kininogen deficiency, factor XII deficiency
**von Willebrand disease
**Lupus anticoagulant
*Elevated PT & PTT
**Deficiences of prothrombin (factor II), factor V, factor X, fibrinogen
**DIC
==References==
Category:Hematology reference pages
Category:Clinical pharmacology
Bone sarcoma

Back to Top
Last updated on 2024-07-23:TBA regimens on this page
TBA variants on this page
Note: this page is for subtype-nonspecific bone sarcoma regimens, and some subtypes with very few subtype-specific regimens. Please see the category page for links to other sarcoma types or use one of these links:
*Ewing sarcoma
*Giant-cell tumor of bone
*Osteosarcoma
=Guidelines=
Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only.
==ESMO/EURACAN/GENTURIS/PaedCan==
*2021: Strauss et al. Bone sarcomas: ESMO–EURACAN–GENTURIS–ERN PaedCan Clinical Practice Guideline for diagnosis, treatment and follow-up EuroPMC
**2018: Casali et al. Bone sarcomas: ESMO-PaedCan-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up EuroPMC
**2014: Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up EuroPMC
**2012: Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up EuroPMC
**2010: Hogendoorn et al. Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up EuroPMC
==NCCN==
*NCCN Guidelines - Bone Cancer
*2013: Biermann et al. Bone cancer. EuroPMC
*2010: Biermann et al. Bone cancer. EuroPMC
*2007: Biermann et al. Bone cancer. EuroPMC
*2005: Biermann et al. Bone cancer clinical practice guidelines. EuroPMC
=Chondrosarcoma, all lines of therapy=
*No standard chemotherapy for grades 1 to 3 conventional chondrosarcoma
*Mesenchymal chondrosarcoma has been treated with Ewing's sarcoma regimens
*Dedifferentiated chondrosarcoma has been treated with osteosarcoma regimens
=Undifferentiated pleomorphic sarcoma (UPS) of bone, all lines of therapy=
*Undifferentiated pleomorphic sarcoma (UPS) of bone has been treated with osteosarcoma regimens
Category:Bone sarcoma regimens
Category:Disease-specific pages
Category:Bone sarcomas
Borofalan-10B (Steboronine)

==Mechanism of action==
From the NCI Drug Dictionary]: A boronated phenylalanine and boron (boron-10) carrier that may be used in boron neutron capture therapy (BNCT), with potential antineoplastic activity. Upon administration, borofalan (10B) is absorbed mostly by tumor cells. When exposed to neutron irradiation, borofalan (10B) absorbs neutrons and self-destructs releasing short-range alpha radiation and 'recoil' lithium in tumor cells, resulting in alpha radiation-induced tumor cell death. This highly selective, localized radiotargeting of tumor cells spares adjacent normal tissues.
==Diseases for which is used==
*Head and neck cancer
==History of changes in PMDA indication==
*2020-03-25: Newly indicated for the treatment of locally unresectable recurrent or unresectable advanced head and neck cancer.
==Also known as==
*Code name: SPM-011
*Brand name: Borofalan
Category:Drugs
Category:Intravenous medications
Category:Radiosensitizers
Category:Head and neck cancer medications
Category:PMDA approved in 2020
Category:Stub
Boston University Medical Center Hematology Oncology Fellowship

For information about other programs, please visit the Hematology Oncology Fellowship Programs Directory.
People affiliated with this program are cordially invited to add additional information.
"The overall goals of the Hematology and Oncology fellowship program are to provide an academically excellent, challenging and personally satisfying training experience for all Fellows. The Facutly work close with Fellows to identify their future career path and maximize their ability to succeed in this path. Fellows learn to grow as expert and compassionate Hematologist and Oncologists, and are provided various opportunities to participate in first rate basic and applied science related to Hematology and Oncology."
==Basic information==
Name: Boston University Medical Center Hematology Oncology Fellowship
Fellowship program website: https://www.bumc.bu.edu/hematology/fellowship-program/
ACGME ID: 1552431027
===Leadership===
*Program Director:
===Fellowship Coordinator===
Jessica Washington
Section of Hematology and Medical Oncology
Boston University Medical Center
650 Albany Street, EBRC X-409
Boston, MA 02118
Phone: 617-638-7521
Fax: 617-638-7530
Email: Jessica.Washington@bmc.org
==Application process and requirements==
https://www.bumc.bu.edu/hematology/fellowship-program/
===Process===
*Applications accepted starting on: July 15
*Application deadline: August 15
*Applications submitted through ERAS
*Interviews in September and October
===Requirements===
*CV
*Personal Statement
*At least three letters of recommendation; one must be from current Program Director
*Medical School Transcripts
*USMLE Scores
*ECFMG Certificate (if applicable)
*Photograph
*Accept J1 Visa
==Statistics==
*Number of fellowship positions available per year: 3 to 5
*Board certification eligibility upon fellowship completion: (depending on what fellow chooses) Hematology and Oncology, Hematology, or Geriatric Medicine and Oncology
*Length of fellowship: 3 to 4 years
==Schedule==
*"There are three main Fellowship tracks from which Fellows can choose, including the standard Hematology and Oncology track, Hematology Research Track, and a Geriatric Oncology Track."
===Year 1===
===Year 2===
===Year 3===
==Affiliated medical facilities==
*Boston Medical Center
==Testimonials==
Testimonials from fellows are welcome. If you are a current or former fellow and would be willing to answer questions from applicants, please tell us and sign up for a free account so you can be listed here. Your email address will not be shared--messages will be sent through the site directly to the email address you provide us.
==Notable faculty==
To be listed by fellowship program.
Category:Hematology & Oncology fellowship programs
Brachytherapy

Ionizing radiation delivered from inside the body, such as through the implantation of radioactive "seeds". 
Some types of brachytherapy include (this list will be expanded in the future):
*Selective internal radiotherapy (SIRT) with yttrium-90 resin microspheres
==Diseases for which it is used==
*Cervical cancer
*Hepatocellular carcinoma
Category:Radiation
Category:Cervical cancer medications
Category:Hepatocellular carcinoma medications
Breast cancer BRCA1 & BRCA2 genetic testing

=Criteria for BRCA1/BRCA2 genetic testing=
This is from a clinical trial protocol and is similar to, but not identical to, the NCCN breast cancer familiar risk assessment guidelines.NCCN Guidelines for Breast and/or Ovarian Genetic Assessment Additional resources can be found at the links below.BRCA1 and BRCA2: Cancer Risk and Genetic Testing (cancer.gov)U.S. Preventive Services Task Force (USPSTF) Genetic Risk Assessment and BRCA Mutation Testing for Breast and Ovarian Cancer Susceptibility
*Breast cancer diagnosed ≤45 years old
*Diagnosed at age ≤50 years old with:
**first, second, or third-degree blood relative with breast cancer diagnosis ≤50 years old 
**and/or epithelial ovarian or fallopian peritoneal cancer at any age
*Diagnosed at age <60 years old with a triple negative breast cancer
*Two breast primaries--that is, bilateral disease or two or more clearly separate ipsilateral primary tumors--when first breast cancer diagnosis occurred prior to age 50
*Personal history of epithelial ovarian, fallopian tube, or primary peritoneal cancer
*Diagnosed at any age with ≥2 first, second, or third-degree relatives with breast and/or epithelial ovarian, fallopian tube, or primary peritoneal cancer at any age
*First or second-degree relative of anybody known to carry a harmful BRCA1 or BRCA2 mutation
*Ashkenazi Jewish descent
*Male breast cancer
*First, second, or third-degree male relative with breast cancer
==References==
Category:Breast cancer pages
Category:Disease-specific pages
Category:General reference pages